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Abstract
Prospective studies focusing on EGFR inhibitors in African Americans with NSCLC have not
been previously performed. In this phase II randomized study, 55 African Americans with NSCLC
received erlotinib 150mg/day or a body weight adjusted dose with subsequent escalations to the
maximum allowable, 200mg/day, to achieve rash. Erlotinib and OSI-420 exposures were lower
compared to previous reports, consistent with CYP3A pharmacogenetics implying higher
metabolic activity. Tumor genetics revealed only two EGFR mutations, EGFR amplification in
17/47 samples, 8 KRAS mutations and 5 EML4-ALK translocations. Although absence of rash
was associated with shorter time to progression (TTP), disease control rate, TTP, and 1-year
survival were not different between the two dose groups, indicating the dose-to-rash strategy
failed to increase clinical benefit. Observed low incidence of toxicity and low erlotinib exposure
suggest standardized and maximum allowable dosing may be suboptimal in African Americans.
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African Americans have a higher incidence and overall mortality of lung cancer compared to
Caucasians.1 The reasons for these disparities have been debated extensively, with
arguments including increased susceptibility and more aggressive biologic features for lung
cancer in African Americans, increased stage of disease at diagnosis, and less aggressive
treatment being offered for early-stage disease.2–6 Survival analyses of patients participating
in cooperative groups clinical trials, which provide for uniform extent of disease and
therapy, showed statistically significantly worse survival at one year for African American
patients.7
This disparity suggests an even more pressing need to develop new anticancer agents to
target lung cancer in this patient population, and the low rate of enrollment of African
Americans in cancer clinical trials is distressing. Moreover, the development of most novel
cancer therapeutic agents occurs exclusive of African Americans. Potential metabolism/
drug-disposition, tolerance, and drug target frequency issues for this ethnicity, which may be
relevant to the safety and/or efficacy of these agents, are often ignored until the drugs are
widely available to the general population.
Interest in molecular targeted therapy for lung cancer has been stimulated by the success of
tyrosine kinase inhibitors (TKis) (i.e., gefitinib, erlotinib) in the setting of NSCLC tumors
harboring epidermal growth factor receptor (EGFR) mutations (approximately 10% of
NSCLC tumors).8–12 Common EGFR activating mutations in NSCLC that are sensitive to
TKI therapies include amino acid deletions in exon 19 and the L858R point mutation at exon
21.8,9 However, erlotinib has been shown to be effective at delaying progression and
improving overall survival (OS) as second- and third-line treatment of NSCLC, even in
unselected patients, thus its current labeling.12,13 Clinical benefit from this agent may
therefore be mediated by additional factors, including tumor mutations outside EGFR
mutation hotspots, pharmacokinetics, pharmacogenetics, gender and race.13,14 Furthermore,
the primary toxicity of this agent, skin rash, has been correlated with response and
survival.15
Recent data suggests pharmacogenetic factors may influence disposition of TKIs. For
example, erlotinib is inactivated through CYP3A4, CYP3A5, CYP1A1 and CYP1A2
metabolism.16,17 Ethnic diversity in cytochrome P450 polymorphisms and enzyme activity
has been well described, and lower erlotinib exposure in African Americans may be
expected due to metabolism from higher CYP3A4/5 and CYP1A1/2 expression compared to
Caucasians.18–20 Furthermore, previous reports evaluating genetic diversity in CYP1A1/2
suggest genotypes less prevalent in African Americans may confer protective effects in
never smokers and increased risk of lung cancer in ever smokers.21,22
In this first of its kind trial, we aimed to prospectively explore the roles of dosing strategy,
smoking, pharmacokinetics, pharmacogenetics, and tumor genetics on outcomes following
erlotinib treatment in African Americans with NSCLC.
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Fifty-eight patients were consented between April 2006 and July 2011. Prior to receiving
treatment, one patient withdrew consent and two patients were removed from study due to
deteriorating health status. Pretreatment characteristics for the 55 patients treated on study
are presented in Table 1. Prior to the 3-month period for response assessment one patient
was removed from the study for evaluation of pulmonary toxicity (day 42). Two additional
patients died prior to response assessment (sudden death due to likely pulmonary embolism
in one patient and clinical deterioration in the other). The remaining 52 patients were
evaluable for the primary endpoint of DCR.
Treatment Toxicity
Fifty-five enrolled patients received therapy. All but 8 patients received 150 mg as starting
dose; 6 and 2 patients received 175 and 200 mg starting doses, respectively. Of the 9
patients in Arm B who did not experience rash during the first cycle, 1 started at the
maximum dose (200 mg), and 5 others did not receive treatment in cycle 2. All 3 patients in
Arm B who were dose escalated started at 150 mg and received maximum escalated doses of
175 mg (n=1) or 200 mg (n=2). Missed doses were minimal overall, especially in cycles 1
and 2, according to patient diaries. Adverse events and treatment-related toxicities
experienced during the trial are summarized in the Table 2. The predominant toxicity was
rash (69% of patients), followed by anorexia and diarrhea (29% each), and nausea (15%).
Overall, toxicities were mild, the majority being of grade 1–2, and only 11 patients (20%)
experienced any grade 3 toxicity. Severe events included a grade 5 gastrointestinal
hemorrhage from a gastric ulcer one month after beginning therapy, a grade 3 interstitial
pneumonitis, a grade 3 dehydration, and a grade 2 bowel obstruction. The patient with
interstitial pneumonitis was removed from study; there were no other withdrawals due to
drug-related adverse events, and no dose reductions for toxicity.
Treatment Efficacy
A total of 12 patients had their disease controlled at 3 months; six for each arm. In arm A
DCR, TTP, and 1-year OS were 23% (95% CI, 9%–44%), 2.8 months (95% CI, 2.5–3.1),
and 30% (95% CI, 13–47%), respectively (Table 3). In arm B DCR, TTP, and 1-year OS
were 23% (95% CI, 9%–44%), 2.4 months (95% CI, 1.5–2.7) and 26% (95% CI, 9–42%).
When patients were stratified by rash, median TTP for patients with rash (n=38) compared
to patients not experiencing rash (n=17) was significantly different (TTP 2.8 vs. 1.8 months,
p=0.036). However, median OS was not significantly different (5.2 vs. 5.3 months, p=0.30).
Severity of rash (grades 2–3 vs. grade 1) was not associated with differences in outcomes.
Non-compartmental pharmacokinetics
Pharmacokinetic data was obtained from 26 patients who received either 150 mg (n=20) or
175 mg erlotinib (n=5) during cycle 1. Figure 1 displays observed concentration-time
profiles for erlotinib and OSI-420 for all patients on cycles 1 and 2. Non-compartmental
parameter estimates for both agents are displayed in Table 4 (Table S1 also displays the data
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separated by dose level). No associations were observed between rash and erlotinib
pharmacokinetics. However, lower mean OSI-420 Cmax was observed in patients with no or
mild rash (grades 0,1; 108 ± 87 ng/mL) compared to patients with more severe rash (grades
2,3; 252 ± 182 ng/mL, p-value = .023, 2-tailed t-test). Furthermore, trends were observed
where current smokers had overall decreased erlotinib AUC0–24 on day 1 of cycle 1 (12.2 ±
6.2 mg/L*hrs, n=11) compared to former/never smokers (17.4 ± 8.9 mg/L*hrs, n=14,
Student’s 2-tailed t-test P = 0.12; see Figure 1 and Supplemental Figure S3). This trend was
not apparent beyond cycle 1, but OSI-420 concentrations did trend higher in smokers
compared to non-smokers in cycle 2 (see Supplemental Figure S4). No statistically
significant associations were observed between erlotinib pharmacokinetics and outcomes,
including progression-free and overall survival.
Pharmacogenetics
Erlotinib is metabolized primarily by CYP3A4/5 and CYP1A1/216,17 and actively excreted
via ABCB1 and ABCG2.23,24 Genetic polymorphisms in these genes were evaluated in the
first 26 patients on study. Additional genotyping was completed for CYP3A4, CYP3A5, and
ABCB1 in 16 additional patients. These data are summarized in Table 5.
Thirty of 39 (77%) patients evaluated were homozygous (*1/*1) or heterozygous (*1/*3) for
the CYP3A5 rs776746 A allele, suggesting they had functional expression of CYP3A5. Of
the 9 patients homozygous for the G allele, only 3 had pharmacokinetic data for both cycles,
thus limiting statistical comparison of this polymorphism and erlotinib or OSI-420
pharmacokinetics. Notably, one of the 3 patients with the G/G genotype had no measureable
OSI-420 during either cycle 1 or 2, potentially reflecting dysfunctional CYP3A5 and limited
formation of the metabolite. AUC0–24 ratios of OSI-420/OSI-774 were low to moderate for
the other two (e.g. 0.022 and 0.060 for cycle 1) compared to remaining patients with PK
data (range 0.005 – 0.129).
Recently, the CYP3A4 rs35599367 (*22) polymorphism was shown to associate
significantly with pharmacokinetics and dose titration of statins, tacrolimus and
cyclosporine.25–28 Data from these studies suggest this polymorphism, which reduces
CYP3A4 activity, is less prevalent in African Americans compared to other populations
studied. Consistent with previous data, all but one of 42 patients evaluated for the
rs35599367 polymorphism were homozygous for the major C allele. This patient was a male
former smoker with EGFR gene amplification who received 150 mg erlotinib. He was also
one of 9 patients homozygous for the CYP3A5*3 G allele. Pharmacokinetic data was not
available for this patient. He achieved grade 1 rash during cycle 1, and his best response was
progressive disease.
Erlotinib is also a known substrate of CYP1A1/2 and multidrug resistance transporters, P-
glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). A total of
13 polymorphic variants were evaluated for these genes. Frequencies for these variants were
similar to those previously reported (see Table 5).20 No significant associations were
identified with these genes.
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We also examined relationships between individual polymorphisms and outcomes from
therapy, including rash and response. No trends or significant associations were found.
Population pharmacokinetics and covariate analysis
The final structural population pharmacokinetic model constructed in this study differed
from previously published models. It utilized one-compartment models for both erlotinib
and OSI-420, and it included inter-individual variability (IIV) parameters on erlotinib
clearance (CL), volume of distribution (V1), and OSI-420 clearance (CLM). A shared ETA
approach was used for CL and CLM, as these were observed to be highly correlated (0.86
correlation coefficient). We also included a single inter-occasion variability (IOV)
parameter, which was estimated on CL. The final residual error model included a single
exponential term for each, erlotinib and OSI-420. The erlotinib first-order absorption rate
constant (Ka) was estimated with poor precision (coefficient of variation, CV > 80%) and
was therefore fixed to 1.04 h−1 based on estimated values from the model and comparison
with other reported values.29,30 Table 6 lists estimated parameter values for the base model.
Notable results include high precision for all base structural model parameters (less than
16% CV), except V2 which had a 62.8% CV. However, IIVCL was estimated with relatively
poor precision with 80.8% CV and a lower confidence interval (CI) boundary of 0.005.
Also, while the shared ETA scale factor had moderate precision (37.0% CV), the base model
bootstrap CI included zero (−148.10, 16.11). Ultimately, when re-evaluating the shared ETA
in the covariate model, it maintained acceptable precision (56.5 CV%), and its bootstrap
confidence interval no longer contained zero. The shared ETA scale factor was therefore
retained in the model to address the high correlation between CL and CLM.
Covariate analysis was conducted to identify sources of variability between patients. Several
covariates were evaluated for effect on model parameters, including age, weight, sex,
smoking status, lean body mass (LBM), pharmacogenetics, and co-medications. Only LBM
was found to significantly reduce the objective function value (OBJ). Only 2 patients
received a CYP3A4/5 inhibitor (voriconazole) or inducer (phenytoin) during therapy. Ten
patients received CYP1A2 inducers (6 omeprazole, 5 insulin, 1 received both). Several
patients received CYP1A1/2 and CYP3A4/5 substrates (the most common of these were
acetaminophen and oxycodone). There were no evident relationships between co-
medications and pharmacokinetics in this study. The population PK parameter estimates in
bootstrap analyses were comparable with those generated using the original data set,
indicating acceptable accuracy and stability of the structural and covariate models (see Table
6). One exception to this was IIVCL, for which the bootstrap median was approximately 6-
fold higher compared to the model estimated value for the original dataset (0.13 vs. 0.02,
respectively). Again, as for the base model, the standard error was relatively high for this
estimate (127.1% CV), and the confidence interval had a lower boundary near zero (0.001).
Tumor Genetics
Tissue in sufficient quantities for evaluation of one or more molecular aberrations was
available from 53 patients. Tumor genetic data is summarized in Table 7. EGFR exon 19
insertions or deletions and exon 21 mutations were successfully evaluated in 45 patients, and
only one patient had an exon 19 short in-frame deletion. Notably, an additional EGFR
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(T790M) mutation31 was present in this patient at a biopsy obtained at progression after two
years on erlotinib. A second patient had an EGFR R776L mutation. Seventeen of 47 patients
(36%) scored positive for EGFR gene amplification (defined as 4–10 EGFR gene copies in
>20% of the tumor cells independent of EGFR to CEP7 ratio). Interestingly, the ALK gene
was translocated in 5 of 39 patients evaluated (13%), and one additional patient had ALK
amplification (>10 copies). KRAS mutations were identified in 8 of 46 patients (17%); of
these KRAS mutations, 6 were of the G12 type32, and two were of uncertain significance
(C/T genotypes in the 5’-UTR, i.e., −9 and −6 positions).
There were no clear associations between DC and absence (5 patients) or presence (7
patients) of most molecular abnormalities (see Table 7). Notably, four of the five patients
with ALK translocation had progressive disease as best response and the fifth was not
evaluable due to death before a restaging scan could be performed. Four of these patients
were current smokers.
DISCUSSION
African Americans suffer from a heavier burden of NSCLC compared to other racial and
ethnic groups within the U.S., and standard treatment regimens produce less favorable
outcomes in African Americans for reasons that are not clear. The approval of EGFR
tyrosine kinase inhibitors has yielded increased availability of treatment choices for patients
with NSCLC, although there is paucity of prospective data regarding the benefits of these
choices for African Americans. To address this gap we set out to prospectively evaluate the
efficacy and toxicity of erlotinib at standard doses and with an alternative dose-to-rash
strategy, as well as to characterize drug disposition, pharmacogenetics, and tumor/host
factors as potential contributors to resistance for these agents in African Americans with
NSCLC.
Erlotinib-related rash has been heralded as a potentially predictive factor for erlotinib
activity. In theory, higher dosing leading to higher erlotinib exposure may lead to higher
EGFR inhibition and pharmacodynamic effects, such as rash and tumor response in patients
with EGFR driven tumors. Interestingly, rash was not correlated with erlotinib exposure,
although it did directly associate with OSI-420 exposure. Absence of rash was correlated
with shorter TTP in our study, although presence of rash was not associated with
improvements in overall survival.
With regard to the dose to rash strategy employed in this study, 18 of the 27 enrolled
patients in Arm B experienced rash during the first cycle, and one additional patient
achieved rash beyond cycle 1. However, only 3 of the 9 potential patients for dose escalation
received higher than standard doses of erlotinib. Five patients were not treated on cycle 2,
and 1 patient had started cycle 1 at the maximum allowable dose of 200 mg. Two of the 3
patients who were dose escalated also reached the maximum allowable dose of 200 mg
without rash, and further escalation was not permitted per protocol design and IND
restrictions at the time the study was initiated.
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The available PK data shows erlotinib exposure in patients receiving 175 mg tended to be
similar to that of patients receiving the 150 mg dose (see Table S1). This is likely a function
of the relatively small number of patients receiving the 175 mg dose level, the relatively
small difference between the doses, and the wide variability observed with TKI therapies.
The data also show that toxicities were overall mild in this group of patients, similar to those
reported in other studies using either 21 day cycles or continuous 150 mg erlotinib doses.in
81 Caucasian and 1242 Asian NSCLC patients12,33 However, in these previous studies, dose
reductions due to adverse events were more frequent (14% and 23%, respectively) compared
to no required dose reductions in our study. Although we did not monitor plasma drug levels
in patients beyond cycle 2, noncompliance was low according to patient dose diaries.
Collectively, this information suggests that further dose escalation may have been tolerated
and that inclusion of plasma AUC for dose escalation decisions (even beyond the 200 mg
level) may have been a more productive strategy.
Pharmacogenetic factors more prevalent within the African American population that are
associated with altered CYP1A and CYP3A activities are well documented and likely alter
PK of drugs available for treatment of NSCLC, such as erlotinib. Pharmacogenetic factors
observed in our study population were in fact suggestive of high CYP3A activity, consistent
with most published literature. Only 2% and 26% of subjects harbored the most functionally
relevant poor metabolizing genotypes, CYP3A4*22 T allele (rs35599367) and CYP3A5*3
A/A genotype (rs776746), respectively. Similarly low prevalence of CYP1A1/2 alleles with
reduced enzymatic activities were also observed in our study population. Only 17% of 24
subjects carry the CYP1A2*1K allele (rs2069536), and on the contrary 50% of 16 subjects
carry the CYP1A2*1F allele (rs762551) which is highly inducible (http://
www.cypalleles.ki.se/, accessed 11 December 2013).
While overall non-compartmental single dose and steady state PK data in this study was
generally similar to that reported in other studies30,34, estimated erlotinib clearance from
nonlinear mixed-effects modeling was higher in our study (6.22 ± 1.52 L/hr) compared to
those reported in any other study (range of population estimates for CL/F, 3.29–5.82 L/
hr)13,30,34–36. Notably, the highest population estimate of CL/F in the previous studies was
obtained by Kraut and colleagues, where erlotinib was combined with docetaxel, a known
inducer of CYP3A enzyme activity37,38.
African Americans also have a historically higher incidence of tobacco smoking,39 which is
associated with higher erlotinib clearance and has therefore been argued to contribute to the
observed outcomes disparities.39,40 Despite randomization in our study, an unequal
distribution of smokers was observed between the control and experimental arms of the
study. Current smokers comprised 48% and 29% of the experimental Arm B and Control
Arm A, respectively. Pharmacokinetics analysis within the limits of the small number of
patients evaluated (n = 26) did show differences (albeit not statistically significant) between
current- and former/never-smokers (Figure 1). These data may indicate the intent to increase
erlotinib exposure in patients treated on the experimental arm was further inhibited by an
increased proportion of smokers randomly assigned to that arm.
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Outcomes data indicated DCR at 3 months was similar to what would be expected with
standard erlotinib doses in a population of previously treated patients with largely EGFR
wild type tumors.41,42,13 As reported by others43 the prevalence of EGFR mutations was
low in this population with high prevalence of tobacco use. However, a surprisingly high
number of patients were found to have ALK translocation and could have benefitted from
now clinically available ALK inhibitors. 44
This is the first study to prospectively evaluate tumor genetics, pharmacogenetics, erlotinib
pharmacokinetics, rash, and clinical outcomes in African Americans with NSCLC receiving
single agent TKI therapy. A relatively high incidence of tumor genetics (KRAS mutations,
EML4-ALK) associated with erlotinib resistance was found. As with other ethnicities,
assessment of tumor genetics prior to treatment is recommended. Furthermore, smoking
history and pharmacogenetic factors consistent with high erlotinib metabolism are
predominantly present in African Americans. The observed apparent higher erlotinib
clearance and mild toxicity data suggest that standard erlotinib dosing in African American
patients may be associated with lower than desired exposure, and would support the
consideration of higher doses from the outset as well as the ability to escalate beyond 200
mg. Overall, the data from this study supports the hypothesis that African Americans may
have, on average, increased erlotinib metabolism compared to other patient populations. A
larger study directly comparing erlotinib PK in African Americans and non-African
Americans receiving the same dose and confirming compliance with drug monitoring will
be necessary to better quantify this potential difference.
MATERIALS AND METHODS
Patient eligibility
The Cancer Institutional Review Boards of The Ohio State University and the University of
North Carolina approved this study (clinicaltrials.gov NCT00230126). All patients provided
written informed consent prior to study entry. Eligible patients included African Americans
18 years or older with measurable, stage IIIB or IV NSCLC, who had received no more than
two chemotherapy regimens. ECOG performance status ≤2, normal organ and marrow
function, and tumor tissue samples from archived or fresh biopsies were required.
Exclusions included pregnancy, prior treatment with EGFR inhibitors, major surgery within
21 days, severe pulmonary insufficiency (pO2 <90%; CO2 >50mmHg) and uncontrolled
inter-current illnesses. Patients receiving HIV combination anti-retroviral therapy were also
excluded. Patients were asked to keep a protocol specific diary and to record any
medications taken during the study.
Randomization, treatment and response evaluation
Patients were randomized 1:1 into two treatment arms by The Ohio State University
Biostatistics Core using fixed-block, non-stratified randomization with a block size of 10. In
Arm A patients received standard 150 mg daily doses of oral erlotinib throughout treatment,
unless dose reductions were required due to toxicity. At the initiation of this trial, erlotinib
had not been fully approved by the U.S. Food and Drug Administration, and the maximal
dose tested in clinical studies and allowed by the manufacturer at that point was 200 mg.
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Patients in Arm B received initial daily oral erlotinib doses of 150 mg, 175 mg, or the
maximum allowable 200 mg based on body weights of <80 kg, 80–90 kg, and >90 kg,
respectively. These doses were maintained throughout cycle 1 (28 days) unless reduction
was required due to toxicity. For cycle 2, doses remained unchanged for all patients who
developed skin rash (grade 1 or greater) during cycle 1, or who started cycle 1 at the
maximum study dose of 200 mg daily. For the remaining patients, doses were increased 25
mg weekly until the dose reached 200 mg or until rash was observed. A CONSORT diagram
and randomization and dosing scheme are available as supplementary data. Patients
completed a daily drug diary to assess compliance, and bottles were returned at the end of
each cycle for pill counts. Treatment was available for continuation until disease progression
or unacceptable toxicity.
Disease response and progression were evaluated using Response Evaluation Criteria in
Solid Tumors (RECIST) every 3 cycles (12 weeks).45 Toxicities were graded according to
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version
3 (CTCAE v3.0). Erlotinib was withheld for patients developing grade 4 non-hematological
toxicity, grade 4 myelosuppression, grade 3 or greater nausea or vomiting unresponsive to
maximal antiemetic therapy, grade 3 or greater asthenia/fatigue or diarrhea, and pulmonary
insufficiency, and discontinued if symptoms did not resolve after 2 weeks.
Pharmacogenetics
Genomic DNA extracted from peripheral blood mononuclear cells was used in multiplexed
analysis of 189 known polymorphisms in drug transporters and metabolizing enzymes as
previously described.46 Additional genotyping was completed for CYP3A4, CYP3A5 and
ABCB1 using standard methods as published previously.28,47
Pharmacokinetics
Pharmacokinetics of erlotinib and active metabolite OSI-420 were determined for a subset
of patients. Plasma samples were collected up to 24 hours after the initial erlotinib dose on
cycle 1, day 1, and again following the first dose on cycle 2, day 1. Both compounds were
simultaneously quantified in each plasma sample using a validated liquid chromatography-
mass spectrometry assay as previously described.30
Non-compartmental pharmacokinetic parameter estimates were generated using WinNonlin
v. 5.2 (Pharsight, Mountain View, CA). Population pharmacokinetic modeling and covariate
analysis were completed with NONMEM v 7.1.2 using methods similar to those described
previously29,30,35. A base structural model was built with first order conditional estimation
considering proportional and additive residual error models, IIV, and IOV on all estimated
parameters. A one compartment model with first order absorption and elimination rate
constant was used for parent drug (i.e., erlotinib), parameterized with the use of Ka, CL and
V1. The erlotinib model was linked to another one compartment model with first order
elimination for active metabolite (i.e., OSI-420), parameterized in terms of metabolite
clearance (CLM) and volume of distribution (V2). The model included an estimate for
fraction (FMET) of erlotinib converted to OSI-420, which was coded as in equation 1,
where FM is an estimated parameter.
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For covariate analyses, continuous covariates, including weight, age and LBM, were
normalized to median values and evaluated as described in equation 2:
(eq. 2)
CONji is the value of the continuous covariate j for individual i, CONj-med is the population
median value of covariate j for all individuals, θi is the individual PK parameter estimate,
θpop is the population parameter estimate for the typical individual, and ηi is the IIV
parameter. Lean body mass was estimated for 25 patients using equation 348
(eq. 3.1)
(eq. 3.2)
where W is body weight in kilograms and H is body height in centimeters. For a male
patient who was a bilateral amputee whose record of original height was not available, we
used “assumed height” to estimate LBM. This was achieved using linear regression to fit a
line for the relationship between height and weight for males.
Pharmacogenetic covariates were dichotomized and evaluated in the model both with
heterozygous genotypes included in the homozygous major and minor allele groups (i.e.
M/m genotypes were coded both as 0 and 1 with M/M always in the 0 category and m/m
always in the 1 category). Similarly, co-medications were dichotomized as 0 (no relevant co-
medications) or as 1 (CYP1A1/2 and CYP3A4/5 substrates, inhibitors, or inducers).
Categorical covariates, including sex, previous smoking status, and current smoking status,
were evaluated as in equation 4:
(eq. 4)
CATji is the value of the categorical covariate j for individual i, and Θj is an estimated
parameter. Using a cutoff of p ≤ .05 for the likelihood-ratio test, corresponding to a decrease
in OBJ of 3.84 or greater, individual covariates were evaluated with forward inclusion,
backward deletion, and forward selection followed by backward elimination to finalize the
covariate model. Model selection in multivariate analysis was based on reduction of OBJ by
≥ 3.84 for forward inclusion, reduction of OBJ ≥ 6.64 (P ≤ 0.01) for backward deletion, and
reduction in residual error and/or IIV of the evaluated PK parameter.
Accuracy and bias of the base and covariate model estimates were evaluated using the
nonparametric bootstrap procedure in the Wings for NONMEM software. The median and
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95% CI were computed for all population pharmacokinetic parameters using sets of
parameter estimates from 1000 bootstrap runs.
Tumor genetics
Formalin fixed, paraffin embedded tissues were obtained from each patient, and genomic
DNA was extracted from sections using standard protocols. Extracted DNA was evaluated
for KRAS (promoter region and G12, G13 codon positions) and EGFR (exons 19 and 21 and
codon positions T790 and R776) mutations by PCR. EML4-ALK fusion and EGFR gene
amplification were evaluated by fluorescence in-situ hybridization. Assays were conducted
at The Ohio State University Molecular Pathology Core Facility according to previously
published methods.49–51 Additional details on these methods are available as supplement.
Data Analyses
The trial utilized a Simon 2-stage minimax design with arms A and B treated as independent
phase II studies. The primary endpoint was disease control rate (DCR = complete response
(CR), partial response (PR) or stable disease (SD) using RECIST criteria) at 3 months. Early
stopping criteria in each arm was set to DCR probability <25% (p0) with alpha and beta both
equal to 0.10. This equated to a first stage accrual of 11 and total accrual of 26 for each
treatment arm. Therefore, if disease control was observed in 3 or more of the first 11
patients treated, the arm would be expanded to accrue 15 additional patients. Furthermore,
DCR probability ≥50% (p1) was required for recommendation of further study. Setting alpha
and beta to 0.10, equated to observation of DCR in a minimum of 10 of the 26 patients
treated for each arm.
Time to progression (TTP) was calculated from date of the first treatment to disease
progression. Patients who had not progressed were censored at the last visit. Deaths
occurring prior to documented progression were also censored. Overall survival (OS) was
determined from the date of the first treatment to death from any cause. Survival curves
were estimated using the method of Kaplan-Meier. Differences between survival curves
were assessed by log-rank test. Correlations between clinical outcomes (response, PR+SD
vs. PD) and rash (Yes vs. No) and tumor genetics (KRAS mutation, ALK translocation, and
EFGR amplification) were studied using Fisher’s exact test. Secondary evaluations to
identify associations between tumor genetics, pharmacokinetics, pharmacogenetics, smoking
status, and outcomes used parametric and non-parametric tests. Analyses were performed
with the R statistical system52 and SAS version 9.2 (SAS Institute).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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AUC area under the concentration vs. time curve
Cmax maximum observed plasma concentration
CI Confidence Interval
CL erlotinib plasma clearance
CR complete response
DC disease control





TTP Time To Progression
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What is the current knowledge on the topic?
African Americans have a higher incidence of lung cancer and less favorable outcomes
from approved therapies compared to other patient populations. The reasons for this are
unclear, and prospective studies conducted to better understand these disparities are
lacking.
What question this study addressed?
The current study was conducted to determine if an alternative dose-to-rash strategy for
the EGFR inhibitor, erlotonib, could produce more favorable outcomes in African
Americans with NSCLC.
What this study adds to our knowledge?
Results in 52 evaluable African American patients indicated the dose-to-rash strategy
produced minimal toxicity, modest improvement in time to progression, and no change in
overall survival. Pharmacokinetic data suggests these patients had relatively high
clearance of erlotinib, which is supported by associated pharmacogenetic features. Tumor
EGFR genetic abnormalities were rare, and EML4-ALK translocations were more
prevalent than expected.
How this might change clinical pharmacology and therapeutics?
Prospective tumor genotyping will improve therapy selection, and pharmacokinetically
guided dosing will increase erlotinib exposure and potentially improve outcomes in
African Americans with NSCLC.
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Figure 1. Pharmacokinetics and Impact of Smoking for Erlotinib (OSI-774) and OSI-420
Semi-log concentration vs. time plots of erlotinib (panels A and B) and OSI-420 (panels C
and D). Each compound was simultaneously measured with a validated LC/MS/MS assay in
patient plasma samples up to 24 hours after the first dose in cycle 1 (panels A and C) and
cycle 2 (panels B and D). Dot plots showing smoking status vs. (E) erlotinib (OSI-774) and
(F) OSI-420 AUC during cycle 1.
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Table 1
Patient characteristics







Number of enrolled patients 28 27 55
Men 17 (60.7) 14 (51.9) 31 (56.4)
Age (years)
  Median 63 59 62
  Range 29–83 37–96 29–96
Weight (Kg)
  Mean 75.8 72.5 74.2
  Standard Deviation 15.2 13.7 14.4
Performance Status
  0 7 (25.0) 6 (22.2) 13 (23.6)
  1 14 (50.0) 17 (63.0) 31 (56.4)
  2 7 (25.0) 4 (14.8) 11 (20.0)
Histologic cell type
  Adenocarcinoma 15 (53.6) 17 (63.0) 32 (58.2)
  Squamous 7 (25.0) 5 (18.5) 12 (21.8)
  NSC not otherwise classified 5 (17.9) 2 (7.4) 7 (12.7)
  Adenosquamous 0 1 1
  Large cell neuroendocrine 1 1 2
  Sarcomatoid 0 1 1
Prior Chemotherapy
  No 4 (14.3) 4 (14.8) 8 (14.5)
  1 regimen 19 (67.9) 15 (55.6) 34 (61.8)
  2 regimens 5 (17.9) 8 (29.6) 13 (23.6)
Previous radiation therapy 11 (39.3) 11 (40.7) 22 (40.0)
Smoking Status
  Current 8 (28.6) 13 (48.1) 21 (38.2)
  Former 15 (53.6) 14 (51.9) 29 (52.7)
  Never 5 (17.9) 0 (0) 5 (9.1)
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Table 2
Treatment Related Toxicities
Toxicity, no. of pts (%) Arm A (n=28) Arm B (n=27) All (n=55)
Any grade 3+ toxicity 5 (18) 6 (22) 11 (20)
Any grade 4/5 toxicity 1 (4) 0 1 (2)
Rash, maximum grade
  Any grade 19 (68) 19 (70) 38 (69)
  Grade 1 12 (43) 10 (37) 22 (40)
  Grade 2 7 (25) 5 (19) 12 (22)
  Grade 3 0 4 (15) 4 (7)
Dermatologic, other than rash*
  Any, grade 1–3 7 (25) 9 (33) 16 (29)
Diarrhea
  Any grade 9 (32) 7 (26) 16 (29)
    Grade 1 7 (25) 7 (26) 14 (25)
  Grade 2 2 (7) 0 2 (4)
    Grade 3+ 0 0 0
Other gastrointestinal
  Anorexia, grade 1–2 5 (18) 9 (33) 14 (25)
  Anorexia, grade 3 2 (7) 1 (4) 3 (5)
  AST elevation 4 (14) 0 4 (7)
  Dehydration, grade 1–2 0 1 (4) 1 (2)
  Dehydration, grade 3 1 (4) 1 (4) 2 (4)
  Hyperbilirubinemia 0 1 (4) 1 (2)
  Nausea, grade 1–3** 2 (7) 6 (22) 8 (15)
  Xerostomia 0 2 (7) 2 (4)
Other
  Pneumonitis, grade 3 1 (4) 0 1 (2)
*
erythema, hyperpigmentation, pruritus, xerodermia.
**
only one grade three nausea was recorded
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Table 3
Efficacy
Number of patients (%)
Arm A (n=26) Arm B (n=26) All (n=52)*
DCR at 3 months 6 (23) 6 (23) 12 (24)
  PR 1 (4) 0 1 (2)
  SD 5 (19) 6 (23) 11 (22)
  PD 20 (77) 20 (77) 40 (78)
Arm A (n=28) Arm B (n=27) All (n=55)**
TTP, months
  Median (95% CI) 2.8 (2.5–3.1) 2.4 (1.5–2.7) 2.6 (1.9– 2.8)
  Range 0.6–14.4 0.3–20.2 0.3–20.2
  1 year progression free rate (%) 10 4 7
Survival, months
  Median 5.3 5.2 5.3
  Range 0.9–37.4 1.3–42.8 0.9–42.8
  1 year survival rate (%) 30 26 28
*
responses based on evaluable patients
**
based on all 55 treated patients
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Table 6
Population PK parameter estimates for erlotinib and OSI-420
Model Term Base model (n=26) Covariate model (LBM, n=26)
Estimate (CV %) Bootstrapmedian (95% CI) Estimate (CV %)
Bootstrap
median (95% CI)
OBJ 968.48 -- 963.26 --
θKa (h−1) 1.04 -- 1.04 --
θCL (L/h) 6.22 (8.5) 6.24 (4.72, 8.11) 6.4 (9.0) 6.37 (4.99, 8.09)
θV1 (L) 284 (15.7) 275.00 (193.00, 448.05) 283 (37.1) 2 74.00 (195.00, 447.03)
θFM 1.41 (12.8) 1.22 (0.47, 3.33) 0.88 (26.4) 1.03 (0.23, 3.49)
θCLM (L/h) 21.5 (8.9) 23.60 (4.76, 47.91) 32.6 (10.4) 27.80 (4.04, 55.60)
θV2 (L) 7.18 (62.8) 7.67 (0.09, 21.91) 11.6 (12.1) 8.99 (0.04, 26.11)
Shared ETA scale
factor, θSE
3.46 (37.0) 3.18 (−148.10, 16.11) 5.96 (56.5) 6.42 (2.29, 577.30)
θLBM -- -- 1.71 (27.8) 1.75 (0.69, 3.08)
IIVCL 0.06 (80.8) 0.24 (0.005, 0.44) 0.02 (127.1) 0.13 (0.001, 0.35)
IIV V1 0.92 (50.5) 0.90 (0.40, 1.33) 0.95 (50.7) 0.92 (0.43, 1.37)
IOV CL 0.38 (55.5) 0.58 (0.29, 0.89) 0.30 (67.9) 0.51 (0.15, 0.85)
Residual error
for erlotinib, ε1
1.2 (37.2) 1.08 (0.66, 1.47) 1.2 (37.1) 1.07 (0.65, 1.48)
Residual error
for OSI-420, ε2
0.78 (23.3) 0.87 (0.37, 1.06) 0.78 (24.2) 0.87 (0.67, 1.06)
OBJ, objective function value; LBM, lean body mass; IIV, inter-individual variability; IOV, inter-occasion variability; CV%, standard error of
estimate expressed as coefficient of variation (%); The shared eta scale factor was estimated as described in the text. IIV, IOV and residual errors
are expressed as variances.
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Table 7
Tumor Genetics
Tested Positive (%) No. of DC at 3m
EGFR mutations 45 2 (4) 1
  EExon 19 indel F 1 1
    Exon 21 mutation 0 0
    R776L mutation 1 0
EGFR gene amplification 47 17 (36) 3
ALK gene translocation 39 5 (13) 0
ALK gene amplification 39 1 1
KRAS mutation 46 8 (17) 2
    G12C (c.32 G>T) 4 0
    G12D (c.33 G>A) 1 0
    G12V (c.33 G>T) 1 1
    5’-UTR (−9C>T, −6 C>T) 2 1
Total 32 7
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